Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson’s Disease Congress

Newton, Massachusetts – December 10, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of clinical trial results with NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease patients. The presentation today at the International Congress on Mental…

NeuroHealing Awarded Qualified Therapeutic Development Project Grant

Grant Supports Development of NH001 for the Treatment of Patients in a Coma, Vegetative State or Minimally Conscious State Following a Traumatic Brain Injury Newton, Massachusetts – November 3, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced that it has…

NeuroHealing Receives Notice of Allowance from the U.S. Patent and Trademark Office for a New Treatment for Premature Ejaculation

Newton, Massachusetts – October 13, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for a patent entitled “Modafinil-based Treatment for Premature Ejaculation.” The patent (US…

NeuroHealing Pharmaceuticals Announces Publication Supporting the Use of NH001 to Treat Patients in a Coma and Issuance of NH001 Patent

Article published in April 2010 issue of Brain Injury Newton, Massachusetts – April 14, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the publication of a scientific article in the journal Brain Injury, supporting the use and further development of NH001…

NeuroHealing Announces Formation of Medical Advisory Board for NH02D Program

Board members include medical experts and leading clinical investigators in the field of men’s sexual health Newton, Massachusetts – August 21, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the formation of a Medical Advisory Board (MAB) to assist the company…

Interim Results of Phase II Trial for the Treatment of Sialorrhea to be Presented at Movement Disorder Society International Congress June 11th

NH004 produced a dose-dependent decrease in drooling in Parkinson’s patients Newton, Massachusetts – June 9, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of pre-planned interim clinical results of a phase II trial with NH004 for the treatment of…

NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting

Positive Effect of Acute NH02D Administration for Treatment of Premature Ejaculation Newton, Massachusetts – April 13, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of positive preclinical results of its premature ejaculation drug NH02D at the American Urological Association…

NeuroHealing Appoints David Gwynne, VP Business Development

Initial Focus on NH02D Program for the Treatment of Premature Ejaculation Newton, Massachusetts – February 2, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced the appointment of David Gwynne, Ph.D. as vice president, business development, responsible for NeuroHealing’s NH02D program…

NeuroHealing Pharmaceuticals to Present at Drug Repositioning Summit in Boston, October 6-7, 2008

Newton, Massachusetts, September 24, 2008. NeuroHealing Pharmaceuticals, a private clinical stage company developing innovative products for individuals with chronic brain injuries and neurodegenerative diseases, will present a talk entitled: “There’s Still Low Hanging Fruit: Three Repositioned Drugs in Clinical Testing for Brain Injury Patients” at the 3rd Annual Drug Repositioning Summit: Finding New Routes to…